Clicky

Hugel Inc(145020)

Description: Hugel, Inc. operates as a biopharmaceutical company in South Korea and internationally. It offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. The company also provides hyaluronic acid filler under the Dermalax, Hyalsense, Revigance, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.


Keywords: Biopharmaceutical Drugs Organ Systems Hyaluronic Acid Toxins Wrinkle Botulinum Toxin Cerebral Palsy Botulism Neurotoxins Eyelid

Home Page: www.hugel.co.kr

61-20, Sinbuk-ro
Chuncheon-si, 24206
South Korea
Phone: 82 3 3255 3882


Officers

Name Title
Mr. Ji-hoon Sohn CEO & Exec. Director
J. T. Kim MD & CFO
Mr. Chang-Jin Lee Sr. MD & Head of Devel. Division
Seonho Han VP and Chief Sales & Marketing Officer
Mr. Soon-Woo Kwon VP & Chief Production Officer
Jennifer Rho MD & Chief Strategy Officer
Minjong Kang MD & Head of Marketing
Jihye Song MD & Head of Cosmetics
Young Mahn Yoo MD & Chief Production Officer

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 2.3077
IPO Date:
Fiscal Year End: December
Full Time Employees: 479
Back to stocks